Lipocine (LPCN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.6M

Revenue (quarter)

$190,099.00

Revenue growth (year over year)

−69.48%

Gross profit (trailing twelve months)

$1.6M

Gross margin

100.00%

Net income (trailing twelve months)

−$11.9M

Net income (quarter)

−$2.6M

Net income growth (year over year)

−18.90%

Net margin

−755.13%

Return on equity

−60.94%

EPS (trailing twelve months)

−$1.85

Book value per share

$2.64

P/E (trailing twelve months)

—

Price to book

0.63

Debt to assets

8.68%

Payout ratio

—

Dividend yield

—

Company profile

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

• Is Lipocine (LPCN) profitable?

  No. Lipocine reported a net loss of $11.9M over the trailing twelve months.

• How much revenue does Lipocine (LPCN) make?

  Lipocine generated $1.6M in revenue over the trailing twelve months, down 69.48% year over year.

• How do I buy stock in Lipocine (LPCN)?

  LPCN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.